Mastocytosis and allergy

Current Opinion in Allergy and Clinical Immunology

Volumn 7, Issue 5, 2007, Pages 387-392

  Greenhawt, Matthew ^a   Akin, Cem ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Anaphylaxis; c kit; Hymenoptera; Mastocytosis; Tryptase

Indexed keywords

ANTIBIOTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYMENOPTERA VENOM; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; STEM CELL FACTOR; TRYPTASE;

ALLERGY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ATOPY; BONE MARROW BIOPSY; CELL ACTIVATION; ENZYME BLOOD LEVEL; GENETIC DISORDER; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MAST CELL; MAST CELL LEUKEMIA; MASTOCYTOSIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SARCOMA; SKIN BIOPSY; URTICARIA;

ANAPHYLAXIS; ARTHROPOD VENOMS; CYTOKINES; HUMANS; MASTOCYTOSIS; TRYPTASES;

EID: 34548669837     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3282a6443e     Document Type: Review

References (52)

1. Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med 2004; 55:419-432.
2. Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006; 8:412-419. A discussion on the methodologic aspects and potential pitfalls of the mutational analysis of the c-kit gene in mastocytosis.
3. Castells M. Mast cell mediators in allergic inflammation and mastocytosis. Immunol Allergy Clin North Am 2006; 26:465-485.
4. Valent P, Horny H, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25:603-625.
5. Valent P, Horny HP, Li CY, et al. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, et al., editors. World Health Organization classification of tumours: pathology and genetics of tumours of the haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp. 291-302.
6. Nettleship E, Tay W. Rare forms of urticaria. BMJ 1869; 2:323.
7. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations, and response criteria. Eur J Clin Invest 2007; 37:435-453. An excellent review summarizing the recommendations for various aspects of diagnostic evaluation and management of patients with mastocytosis.
8. Carter MC, Metcalfe DD. Paediatric mastocytosis. Arch Dis Child 2002; 86:315-319.
9. Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001; 25:519-528.
10. Escribano L, Akin C, Castells M, et al. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets 2006; 5:61-77.
11. Butterfield JH. Systemic mastocytosis: clinical manifestations and differential diagnosis. Immunol Allergy Clin North Am 2006; 26:487-513. A comprehensive overview of differential diagnosis of symptoms in patients presenting with suspected mastocytosis. Helps in understanding why the diagnosis of mastocytosis cannot be based on symptoms alone.
12. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92:10560-10564.
13. Sotlar K, Escribano L, Landt O, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003; 162:737-746.
14. Akin C, Metcalfe DD. Occult bone marrow mastocytosis presenting as recurrent systemic anaphylaxis [abstract]. J Allergy Clin Immunol 2003; 111:S206.
15. Sonneck K, Florian S, Mullauer L, et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol 2007; 142:158-164.
16. Akin C, Schwartz LB, Kitoh T, et al. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology. Blood 2000; 96:1267-1273.
17. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006; 26:451-463.
18. Caughey GH. Tryptase genetics and anaphylaxis. J Allergy Clin Immunol 2006; 117:1411-1414.
19. Shanmugam G, Schwartz LB, Khan DA. Prolonged elevation of serum tryptase in idiopathic anaphylaxis. J Allergy Clin Immunol 2006; 117:950-951.
20. Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327:380-384.
21. Soto D, Malmsten C, Blount JL, et al. Genetic deficiency of human mast cell alpha-tryptase. Clin Exp Allergy 2002; 32:1000-1006.
22. Akin C, Soto D, Brittain E, et al. Tryptase haplotype in mastocytosis: relationship to disease variant and diagnostic utility of total tryptase levels. Clin Immunol 2007; 123:268-271.
23. Schwartz LB, Sakai K, Bradford TR, et al. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 1995; 96:2702-2710.
24. Schwartz LB. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res 2001; 25:553-562.
25. Hsieh FH, Alam MM, Lichtin AE. Elevated total serum tryptase levels in patients with postural orthostatic tachicardia syndrome (POTS): a case series [abstract]. J Allergy Clin Immunol 2005; 115:S248.
26. Buckley MG, Variend S, Walls AF. Elevated serum concentrations of beta-tryptase, but not alpha-tryptase, in sudden infant death syndrome (SIDS): an investigation of anaphylactic mechanisms. Clin Exp Allergy 2001; 31:1696-1704.
27. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101:4660-4666.
28. Sperr WR, Jordan JH, Baghestanian M, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001; 98:2200-2209.
29. Sperr WR, Jordan JH, Stehberger B, et al. Detection of elevated serum tryptase levels in MDS. Blood 1999; 94:287b.
30. Kors JW, van Doormaal JJ, de Monchy JG. Anaphylactoid shock following Hymenoptera sting as a presenting symptom of systemic mastocytosis. J Intern Med 1993; 233:255-258.
31. Haeberli G, Bronnimann M, Hunziker T, et al. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003; 33:1216-1220.
32. Rueff F, Placzek M, Przybilla B. Mastocytosis and Hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2006; 6:284-288.
33. Ludolph-Hauser D, Rueff F, Fries C, et al. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001; 357:361-362.
34. Kranke B, Sturm G, Aberer W. Negative venom skin test results and mastocytosis. J Allergy Clin Immunol 2004; 113:180-181.
35. Oude Elberink JN, de Monchy JG, Kors JW, et al. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997; 99:153-154.
36. Fricker M, Helbling A, Schwartz L, et al. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 1997; 100:11-15.
37. Izikson L, English JC 3rd, Zirwas MJ. The flushing patient: differential diagnosis, workup, and treatment. J Am Acad Dermatol 2006; 55:193-208. Detailed discussion of various flushing syndromes.
38. Metcalfe DD. Differential diagnosis of the patient with unexplained flushing/ anaphylaxis. Allergy Asthma Proc 2000; 21:21-24.
39. Hartmann K, Henz BM. Mastocytosis: recent advances in defining the disease. Br J Dermatol 2001; 144:682-695.
40. Brockow K. Urticaria pigmentosa. Immunol Allergy Clin North Am 2004; 24:287-316.
41. Taskapan O, Harmanyeri Y. Evaluation of patients with symptomatic dermographism. J Eur Acad Dermatol Venereol 2006; 20:58-62.
42. McClelland VM, Brookfield DS. Palpation reveals the diagnosis. Arch Dis Child 2005; 90:1278.
43. Ditto AM, Harris KE, Krasnick J, et al. Idiopathic anaphylaxis: a series of 335 cases. Ann Allergy Asthma Immunol 1996; 77:285-291.
44. Webb LM, Lieberman P. Anaphylaxis: a review of 601 cases. Ann Allergy Asthma Immunol 2006; 97:39-43. Large case series from a tertiary referral center for anaphylaxis.
45. Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast cell population with clonal markers in a subset of patients with idiopathic anaphylaxis. Blood 2007, in press.
46. Hungness SI, Singer AM, Akin C. Food-dependent exercise-induced anaphylaxis associated with clonal mast cells carrying an activating c-kit mutation [abstract]. J Allergy Clin Immunol 2007; 119:S29.
47. Caplan RM. The natural course of urticaria pigmentosa: analysis and follow-up of 112 cases. Arch Dermatol 1963; 87:146-157.
48. Muller U, Helbling A, Hunziker T, et al. Mastocytosis and atopy: a study of 33 patients with urticaria pigmentosa. Allergy 1990; 45:597-603.
49. Brockow K, Akin C, Huber M, et al. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrowpathology. J Am Acad Dermatol 2003; 48:508-516.
50. Gonzales de Olano D, de la Hoz Caballer MB, Nunez-Lopez R, et al. Prevalence of allergy and anaphylaxis in 210 patients with mastocytosis: a study from the Spanish network on mastocytosis (REMA) [abstract]. J Allergy Clin Immunol 2007; 119:S28.
51. Codreanu F, Morisset M, Renaudin JM, et al. Drug anaphylaxis as presentation of systemic mastocytosis: about 7 case reports [abstract]. J Allergy Clin Immunol 2007; 119:S28.
52. Brockow K, Jofer C, Ring J. Anaphylaxis in patients with mastocytosis: a prospective study on prevalence, severity and trigger factors in 121 patients [abstract]. J Allergy Clin Immunol 2006; 117:S307.